Internal medicine

Immunome Appoints Sandra M. Swain to Board of Directors

Retrieved on: 
Thursday, April 25, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, MedStar Health, University, Bangladesh Technical Education Board, Pfizer, Genetic distance, Professor, Vanderbilt University, Doctor of Philosophy, National Cancer Institute, Dean (education), IND, ASCO, Patient, National Institutes of Health, Society, Acquisition, Executive Committee, Georgetown University Medical Center, Internal medicine, Investigational New Drug

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors.
  • “Immunome is pleased to welcome Sandra to the Board of Directors, especially given her extensive experience as a successful clinical researcher,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
  • Dr. Swain served on the board of directors of the American Society of Clinical Oncology (ASCO) from 2008-2013 and was ASCO President 2012-13.
  • Dr. Swain previously served on the board of directors of Seagen Inc. from November 2022 until its acquisition by Pfizer Inc. in December 2023.

Joint Study with Leading US Hospital to Assess Impact of FeelBetter’s Precision Population Health Platform on Polypharmacy Patient Management

Retrieved on: 
Tuesday, April 23, 2024
Biometrics, Other Health, Pharmaceutical, Oncology, Software, Artificial Intelligence, Mental Health, Hospitals, Data Management, Technology, Practice Management, Nursing, Clinical Trials, Managed Care, General Health, Surgery, Health, Health Technology, Conditional sentence, Society, Hospital, Risk, Polypharmacy, Electronic health record, MD, Partnership, Research, ARM, Entrepreneurship, Internal medicine, AcademyHealth, Patient, Master of Science, SGIM, Harvard Medical School

FeelBetter , the leading provider of polypharmacy patient management technology and pioneer of Pharmaco-Clinical Intelligence, today announced a collaboration on a prospective research study with investigators at Brigham and Women’s Hospital in Boston.

Key Points: 
  • FeelBetter , the leading provider of polypharmacy patient management technology and pioneer of Pharmaco-Clinical Intelligence, today announced a collaboration on a prospective research study with investigators at Brigham and Women’s Hospital in Boston.
  • The research will assess the impact of FeelBetter’s AI-based Precision Population Health Platform on polypharmacy patient management.
  • “Our previous study showed that its platform can be used to identify which patients are at the highest risk of polypharmacy-related adverse events.
  • Study results also indicated that, when paired with a medication management intervention, FeelBetter's technology could potentially reduce healthcare utilization and expenses, and aid in improving patient outcomes.

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Retrieved on: 
Thursday, April 18, 2024
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Medical school, University, Cancer, The Lancet, Journal of Clinical Oncology, Lung cancer, Clinical Cancer Research, NDA, Pancreatic cancer, Hematology, Internal medicine, RAS, Nektar, Leukemia, Patient, Data management, Northeast Ohio Medical University, Blood, Nektar Therapeutics, Therapy, Journal, Verastem Oncology

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy.
  • “John is a recognized leader in oncology with broad expertise across cancer research and development, business development and organizational leadership, and we welcome him to the Verastem team,” said Dan Paterson, president and chief executive officer of Verastem Oncology.
  • Dr. Hayslip received his medical degree from Northeast Ohio Medical University and a master’s degree in clinical research from the Medical University of South Carolina.
  • Following his residency in internal medicine, Dr. Hayslip completed his fellowship in hematology-oncology at the Medical University of South Carolina, leading to dual board certifications in both hematology and medical oncology.

Lindora, Leader in Wellness Solutions, Signs First Wave of Multi-Unit Franchise Agreements in Key Markets

Retrieved on: 
Monday, April 15, 2024
Professional Services, Business, Health, Other Health, Fitness & Nutrition, General Health, BFT, Internal medicine, Pilates, Weight loss, Partnership, Dance, AKT, Yoga, HRT, Exercise, Acquisition, Medicine, Hill of Row, Boxing, Marketing, Running, Hormone replacement therapy, Pharmaceutical industry

Following its acquisition by Xponential Fitness , Lindora has franchise agreements with owners from diverse backgrounds including technology, software development, real estate, marketing and sales, personal training, and finance.

Key Points: 
  • Following its acquisition by Xponential Fitness , Lindora has franchise agreements with owners from diverse backgrounds including technology, software development, real estate, marketing and sales, personal training, and finance.
  • As the largest global franchisor of health and wellness brands, Xponential brings unparalleled experience and resources to support Lindora franchisees.
  • Founded in 1971 in Southern California, Lindora is a leading provider of medically guided weight management programs and wellness solutions.
  • Lindora is headquartered in Irvine, CA and backed by Xponential Fitness, the largest franchisor of boutique health and wellness brands.

QT Imaging’s Breast Acoustic CT™ Scanner to be Offered at The Center for New Medicine to Advance Personalized Prevention and Detection of Breast Cancer

Retrieved on: 
Thursday, April 11, 2024
Oncology, Medical Devices, Health, Consumer, Women, Biotechnology, FDA, Radiation, Woman, Internal medicine, Breast, Partnership, Research, 3D, Patient, Medicine, Medical director, Breast cancer, Medical imaging

The Center for New Medicine is one of the largest integrative medical clinics in North America, providing a personalized approach to health care including cancer prevention, its early detection, and internal medicine.

Key Points: 
  • The Center for New Medicine is one of the largest integrative medical clinics in North America, providing a personalized approach to health care including cancer prevention, its early detection, and internal medicine.
  • With the incorporation of the QT Imaging Breast Acoustic CT™ Scanner, the Center for New Medicine will expand their innovative services in women’s and breast health.
  • There is tremendous opportunity for new technology to advance women’s health, especially in breast cancer detection and treatment.
  • QT Imaging Breast Acoustic CT™ Scanner is the only 3D imaging device to receive FDA clearance for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast.

AMBOSS Acquires NEJM Knowledge+ from NEJM Group, Setting a New Standard in Medical Education and Clinical Practice

Retrieved on: 
Thursday, April 25, 2024
Learning, Health care, Entrepreneurship, Acquisition, Physician, NEJM, Evidence-based medicine, Pediatrics, Health, Internal medicine, Student, Family medicine, Nursing

AMBOSS is renowned for its expert medical library, intuitive learning platform, and user interface designed to easily obtain and retain medical knowledge.

Key Points: 
  • AMBOSS is renowned for its expert medical library, intuitive learning platform, and user interface designed to easily obtain and retain medical knowledge.
  • "We are really excited to bring NEJM Knowledge+ into the AMBOSS family," said Dr. Madjid Salimi, Co-Founder and Co-CEO of AMBOSS.
  • "NEJM Group has always been at the forefront of disseminating medical knowledge and improving patient care," said David Sampson, Vice President, Chief Publishing Officer of NEJM Group.
  • Through this acquisition, AMBOSS and NEJM Group reaffirm their commitment to enhancing medical education and clinical practice.

Seed Health Appoints Microbiome Pioneer Zain Kassam, M.D., M.P.H., as Chief Medical Officer

Retrieved on: 
Wednesday, April 24, 2024
Western University, Harvard University, Nature Biotechnology, Public health, Chairperson, Abstract, Health, McMaster University, OpenBiome, FMT, Janssen, IPO, Therapy, Science, Ecology, Alumni, Internal medicine, Bacillota, Longevity, Growth, MIT, Medical device

BOSTON, April 24, 2024 /PRNewswire/ -- Seed Health, a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer. An award-winning physician-scientist, Dr. Kassam has played a pivotal role in the advancement of microbiome science for over a decade. His extensive body of work includes over 200 peer-reviewed publications and abstracts, including in The New England Journal of Medicine, Nature Biotechnology, and Gastroenterology, and co-authoring international clinical practice guidelines. He has championed more than 30 Phase I-III clinical trials with top-tier academic institutions across multiple therapeutic areas. As Chief Medical Officer, Dr. Kassam will collaborate with Chief Scientific Officer, Dirk Gevers, Ph.D., to oversee Seed Health's R&D portfolio. He will expand the company's gut microbiome program and guide upcoming launches in the vaginal and skin microbiome sectors, as well as in brain health, metabolic health, and longevity.

Key Points: 
  • Dr. Kassam will lead Seed Health's clinical research and medical affairs, driving the
    BOSTON, April 24, 2024 /PRNewswire/ -- Seed Health , a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer.
  • As Chief Medical Officer, Dr. Kassam will collaborate with Chief Scientific Officer, Dirk Gevers, Ph.D., to oversee Seed Health's R&D portfolio.
  • He will expand the company's gut microbiome program and guide upcoming launches in the vaginal and skin microbiome sectors, as well as in brain health, metabolic health, and longevity.
  • Before joining Seed Health, Dr. Kassam co-founded and was Chief Medical Officer at two foundational microbiome therapeutics companies, OpenBiome and Finch Therapeutics.

Dr. Anthony Fletcher Installed as President of the Association of Black Cardiologists

Retrieved on: 
Tuesday, April 23, 2024
Education, Xavier University, George Washington University Hospital, University, Blood, ABC, University of Cincinnati, Heart, Capacity building, Chairperson, Doctor of Philosophy, FACC, Cardiology, Cardiovascular disease, MBA, Internal medicine, ABC Board

WASHINGTON, April 23, 2024 /PRNewswire/ -- The Association of Black Cardiologists (ABC) proudly announces it 20th President, Dr. Anthony Fletcher.

Key Points: 
  • WASHINGTON, April 23, 2024 /PRNewswire/ -- The Association of Black Cardiologists (ABC) proudly announces it 20th President, Dr. Anthony Fletcher.
  • He is an interventional cardiologist with CHI St. Vincent Cardiology and Medicine Clinic in Little Rock, Arkansas.
  • Dr. Fletcher is a graduate of Xavier University in Cincinnati, Ohio, and the University of Cincinnati College of Medicine.
  • During his presidency, Dr. Fletcher is committed to forging the mission and vison of the ABC by ensuring inclusivity and diversity for all.

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Retrieved on: 
Tuesday, April 23, 2024
Third Rock Ventures, Factorization of polynomials, University, Cancer, Flare, Immunology, Biostatistics, Hospital, Pharmacovigilance, ACRS, Arena, GSK plc, Cardiology, Head, Virology, Pharmacy, Science, Bristol Myers Squibb, Neurology, Acquisition, DSM-IV codes, Public key certificate, Fibrosis, Arena Pharmaceuticals, Harvard Medical School, Pfizer, BMS, Internal medicine, FRCP, Drug development, Therapy, Massachusetts General Hospital, Biotechnology, Growth, Pharmaceutical industry

CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately.

Key Points: 
  • CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately.
  • Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies.
  • He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.
  • Dr. Manion joins Flare Therapeutics from Aclaris Therapeutics, Inc. (NASDAQ: ACRS), where he was President and Chief Executive Officer.

TGH North Announces TGH Brooksville and TGH Spring Hill Board of Managers

Retrieved on: 
Monday, April 22, 2024
Rollins College, Tampa General Hospital, Teaching, Partnership, Business, Culture, Charity Hospital, Damascus University, Emergency medicine, Council, Love, Emergency, Executive Committee, Harvard University, Safety, Hospital, Research, TGH, Family, Bank, Foreign policy, Sale, Damascus Hospital, University, Gastroenterology, Internal medicine, University School, History, Acquisition, Physician, Management

BROOKSVILLE, Fla., April 22, 2024 /PRNewswire/ -- TGH North, a division of Tampa General Hospital, announced its new TGH Brooksville and TGH Spring Hill board of managers, which will serve as a guide for leadership and oversee operations. The board convened Wednesday in Brooksville for its inaugural meeting.

Key Points: 
  • BROOKSVILLE, Fla., April 22, 2024 /PRNewswire/ -- TGH North , a division of Tampa General Hospital, announced its new TGH Brooksville and TGH Spring Hill board of managers, which will serve as a guide for leadership and oversee operations.
  • M. Rodwan Hiba, M.D., has been a member of the medical staff at TGH Brooksville and TGH Spring Hill since 1999.
  • The board of managers at TGH North serves as the governing body for the operations in Hernando County.
  • TGH North was formed on December 1, 2023, when Tampa General completed the acquisition of the Bravera Health network.